Background Second lung primaries occur at a rate of 2% per patient per year after curative resection for non-small cell lung carcinoma (NSCLC). The aim of this study was to evaluate the role of fluorescence bronchoscopy using the Xillix (R) LIFE-Lung Fluorescent Endoscopy System TM (LIFE-Lung system) in the surveillance of patients for second NSCLC primaries after resection or curative photodynamic therapy (PDT).
INTRODUCTION
Only about 14% of patients with invasive lung cancer can be cured using conventional treatment modalities (surgery, chemotherapy and/or radiation therapy) [1] . By the time a carcinoma ofthe lung produces symptoms and is diagnosed, it has usually progressed locally beyond resectability (Stage IIIB) way to significantly impact on the high mortality from lung cancer appears to be identification of the disease at an earlier stage, prior to its becoming a systemic disease.
The histological response of the respiratory mucosa to exogenous environmental stresses is a predictable progression from normal mucosa through metaplasia, dysplasia, carcinoma in situ (CIS) and eventually resulting in invasive carcinoma [2] . On an average, a period of four to five years exists during which time individuals exfoliate markedly atypical cells into bronchial secretions that antedates the progression to an invasive tracheobronchial carcinoma [3] . During this exfoliative period, the tracheobronchial trees of these individuals may harbor occult intraepithelial neoplasias (IENs) below the resolution of conventional bronchoscopy but potentially detectable by fluorescent bronchoscopy.
Currently, lung carcinomas in high-risk patients are most commonly identified through periodic sputum cytologic analysis and/or standard chest X-rays. Both of these methodologies are less than optimum screening modalities; the former does not localize the lesion within the tracheobronchial tree and the latter is neither sensitive nor specific for the malignancy. In a normal bronchus, the predominant source of fluorescence is the submucosa [6] . Several The standard interval between PDT treatments with curative intent at our institution is between 4 and 6 weeks. We opted to perform a LIFE exam at that time, recognizing that the specificity of the LIFE bronchoscopic exam post-PDT might be lower than previously reported by Lam et al. [7] due to the retained Photofrin IITM. We accepted the potentially higher number offalse positives detected by LIFE because delaying the exam beyond 6 weeks post-PDT (to allow for further clearance of Photofrin II) could compromise patient care if additional PDT was required.
All surveillance LIFE bronchoscopic exams were conducted as outpatient procedures using intravenous conscious sedation. Aerosolized and viscous 1% lidocaine, as well as cetacaine spray, were employed to achieve topical anesthesia of the oroand hypopharynx. Lidocaine CIS and microinvasive lesions treated with PDT were re-examined with both WLB and LIFE bronchoscopy at four months post-PDT to determine the durability of response. Additional PDT and/or surgical resection was performed if there was histologic evidence of recurrence or persistence of severe dysplasia and/or progression to an invasive carcinoma. All pathologic evaluations of the mucosal biopsies were made without knowledge of bronchoscopic findings. The negative predictive value of LIFE bronchoscopy in post-resection patients was 0.97 (Table II) .
We performed 11 LIFE exams on five patients that were status-post-PDT with curative intent.
Three of these patients also had a resection of a separate NSCLC primary. Eight lesions were identified in these five patients (one patient had four separate lesions) treated definitively with nine courses of PDT: two patients required one course, two patients required two courses and one patient Only one lesion was detected in the post-PDT subset of patients and it was detected by both LIFE and WLB. No IENs were identified in the post-PDT subset of patients (Table III) .
DISCUSSION
In 1998 over 160,000 individuals died of lung cancer in the United States alone, exceeding the total mortality from breast, prostate, pancreatic and all lymphomas and leukemias. Much controversy exists with respect to the current practice and future standard ofcare with respect to screening for breast, colon and prostrate cancer [8] . "Virtually all organizations, however, concur that screening for lung cancer is not justified.., the American College of [9] . A recent critical review of 10 prospective trials on screening for lung cancer by Strauss et al. including four randomized controlled trials, two non-randomized controlled trials and four uncontrolled trials failed to show a reduction in lung cancer mortality between the experimental and control populations in the six controlled trials [10] .
The efficacy of screening for second lung cancer primaries in the subset of high-risk patients with a history of prior NSCLC is unknown. In addition, technological advances in both the diagnosis and the treatment ofearly tracheobronchial mucosal lesions render the conclusions drawn from prior trials of historical significance only.
In March 1998 Lam et al. [7] published data from the multi-institutional clinical study that showed that the LIFE-Lung system, when used as an adjunct to conventional WLB, improved the physician's ability to identify moderate/severe dysplasia or worse. In this trial the efficacy of fluorescence bronchoscopy in patients with suspected or proven NSCLC was assessed: 154 of the 173 patients in this trial were suspected ofhaving or known to have lung cancer based on symptoms and/or abnormal chest radiograph (114 patients), abnormal sputum cytology (29 patients) and 11 patients were known to have lung cancer based on prior investigations. The relative sensitivity of LIFE versus WLB for invasive carcinoma was only 1.46 (Table III) . We speculate that this may be secondary to retained photofrin in these patients (Fig. 4) [14] . LIFE bonchoscopy affords investigators the opportunity to identify early mucosal abnormalities prior to the phenotypic expression of a transformed cell, i.e. before the development of an invasive carcinoma. Biopsy spec-
